Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 4—April 2019
Research

Differences in Neuropathogenesis of Encephalitic California Serogroup Viruses

On This Page
Materials and Methods
Results
Discussion
Cite This Article
Figures
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Tables
Table 1
Table 2
Downloads
Article
RIS [TXT - 2 KB]
Article Metrics
Metric Details
22
citations of this article
EID Journal Metrics on Scopus
Author affiliations: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA

Cite This Article

Abstract

The California serogroup of orthobunyaviruses comprises a group of mosquitoborne viruses, including La Crosse (LACV), snowshoe hare (SSHV), Tahyna (TAHV), Jamestown Canyon (JCV), and Inkoo (INKV) viruses, that cause neurologic disease in humans of differing ages with varying incidences. To determine how the pathogenesis of these viruses differs, we compared their ability to induce disease in mice and replicate and induce cell death in vitro. In mice, LACV, TAHV, and SSHV induced neurologic disease after intraperitoneal and intranasal inoculation, and JCV induced disease only after intranasal inoculation. INKV rarely induced disease, which correlated with less viral antigen in the brain than the other viruses. In vitro, all viruses replicated to high titers; however, LACV, SSHV, and TAHV induced high cell death, whereas JCV and INKV did not. Results demonstrated that CSG viruses differ in neuropathogenesis in vitro and in vivo, which correlates with the differences in pathogenesis reported in humans.

The California serogroup (CSG) of orthobunyaviruses comprises a large group of closely related mosquitoborne, trisegmented, negative-sense RNA viruses in the family Peribunyaviridae of the order Bunyavirales. La Crosse virus (LACV), snowshoe hare virus (SSHV), Tahyna virus (TAHV), Jamestown Canyon virus (JCV), and Inkoo virus (INKV) are members of the CSG that have been reported to cause neurologic disease in humans. LACV, SSHV, TAHV, and INKV primarily cause neuroinvasive disease in children; however, the incidence differs for each virus (1–3). LACV is the leading cause of pediatric viral encephalitis in the United States, responsible for ≈50–100 reported cases per year. SSHV and TAHV only cause several reported cases of neuroinvasive disease annually (1,2,4–6), and TAHV disease most often manifests as influenza-like symptoms and only rarely leads to encephalitis (2,7). INKV has caused the fewest cases of human disease. However, several confirmed neuroinvasive cases have occurred in Finland, and children had more severe disease than adults (3). In contrast, JCV appears to preferentially cause neuroinvasive disease in adults, and several cases occur every year in the United States and Canada (1,8). Because the number of reported cases increased substantially in the 2010s, JCV is considered a potentially emerging arboviral disease (9).

The number of actual cases caused by these CSG viruses is likely underreported because of the difficulty of diagnosing these viral infections. Patients who do not seek medical treatment and those with less severe disease might not be included in case reports. All 5 viruses have high reported seroprevalence rates in endemic regions: ≈1%–27% for LACV, JCV, and SSHV; ≈24%–51% for INKV; and up to 80% for TAHV (1,2,10–12).

Figure 1

Thumbnail of Global distribution, phylogenetic relationship, and vectors and hosts of the 5 California serogroup (CSG) viruses included in study of neuropathogenesis of encephalitic CSG viruses. A) These viruses are found across the globe, primarily throughout North America, Europe, Asia, and Africa (1,4,8,10,12–29). Several of these viruses have overlapping regions of distribution (as indicated by diagonal patterns), including in the United States, where LACV, SSHV, and JCV are all present, and

Figure 1. Global distribution, phylogenetic relationship, and vectors and hosts of the 5 California serogroup (CSG) viruses included in study of neuropathogenesis. A) These viruses are found across the globe, primarily throughout North...

These CSG viruses have differing but overlapping geographic distributions (Figure 1, panel A). LACV, JCV, and SSHV are all found in the United States; JCV and SSHV extend into Canada, and SSHV extends into Russia (1,2,4,8,10,13–28). Although TAHV and INKV are primarily found in Europe, TAHV extends into Africa and Asia, and INKV is limited to northern Europe and Russia (2,3,12,29,34–36). These CSG viruses use a variety of mosquito vectors, primarily in the Aedes and Ochlerotatus genera, and mammalian host species, including small rodents (SSHV, LACV, and TAHV), hares (SSHV, TAHV, and INKV), and deer (JCV) (Figure 1, panel B) (1,2,12,22,29,31–33).

Despite their differing and widespread geographical distributions, the CSG viruses are genetically closely related. The large segment encodes the viral RNA-dependent RNA polymerase, the medium segment encodes 2 envelope glycoproteins and a nonstructural protein, and the small segment encodes the nucleocapsid and a second nonstructural protein (NSs), which in LACV is a type I interferon antagonist (37,38). Across all 3 segments, JCV and INKV are the most closely related to each other, with 84%–92.4% nucleotide identity, followed by LACV and SSHV with 79.4%–89.1% nucleotide identity (30). TAHV has ≈72.5%–84.7% nucleotide identity with LACV and SSHV and 69.2%–80.3% with JCV and INKV (30).

In mouse studies of LACV, weanling C57BL/6 mice were susceptible to neurologic disease after intraperitoneal inoculation, but adult mice were not, demonstrating age-dependent susceptibility to disease that mimics clinical disease in humans (39). Certain strains of TAHV, but not JCV, have been shown to cause neurologic disease in weanling Swiss Webster mice after intraperitoneal inoculation, although both viruses were capable of replicating in the brain after intracranial inoculation (40,41). In these studies, only weanling mice were used, and thus, age-dependent susceptibility was not evaluated.

Determining how LACV, SSHV, TAHV, JCV, and INKV differ in pathogenesis in animal and cell culture models could help explain their differing disease outcomes in humans. However, a direct comparison between these viruses in their ability to invade the central nervous system (CNS) and induce neuronal damage has not been investigated. In this study, we investigated age-related differences in pathogenesis of LACV, SSHV, TAHV, JCV, and INKV. We examined the ability of these viruses to enter the CNS and cause disease in mice and their ability to replicate in neurons and induce cell death in vitro.

Materials and Methods

Cells and Viruses

All cell culture reagents were from Gibco (http://www.biosciences.ie/gibco) unless otherwise specified. We maintained Vero cells in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (Atlas Biologicals, https://atlasbio.com) and 1% penicillin/streptomycin solution; C6/36 cells in minimum essential medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 1× nonessential amino acids, and 1% penicillin/streptomycin; the neuroblastoma cell line SH-SY5Y (American Type Culture Collection [ATCC], https://www.atcc.org) in a 1:1 ratio of Eagle minimum essential medium (ATCC) and F-12K (ATCC) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin; and H9 human embryonic stem cell–derived human neural stem cells (hNSCs; Gibco, https://www.fishersci.com) in KnockOut DMEM/F-12 supplemented with 1× GlutaMAX-I Supplement, 20 ng/mL basic fibroblast growth factor, 20 ng/mL epidermal growth factor, 2% StemPro neural supplement, and 1% penicillin/streptomycin. We seeded hNSCs on plates or flasks treated with 20 μg/mL fibronectin in Dulbecco phosphate-buffered saline for 1 h at 37°C. We passaged stocks of LACV (human 1978 strain), JCV (strain 61V2235), TAHV (strain 92 Bardos), SSHV (1976), and INKV (SW AR 83-161), all kindly provided by Stephen Whitehead (Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA), in Vero or C6/36 cells up to 3 times.

Inoculation of Mice

All mouse experiments were approved by the Rocky Mountain Laboratories Animal Care and Use Committee (Hamilton, Montana, USA) and performed in accordance with National Institutes of Health guidelines under protocol 2016-061-E. We used C57BL/6 mice for all experiments.

We inoculated weanlings at 21–23 days of age, adults at 6–8 weeks of age, and aged mice at 19–34 weeks of age. We diluted the viruses in phosphate-buffered saline (PBS). For intraperitoneal inoculations, we injected mice with 105 or 103 PFU of virus in a volume of 200 μL. For intranasal inoculations, we inoculated mice with 104 or 102 PFU of virus in a volume of 20 μL. We anesthetized mice with isoflurane before inoculation. After inoculation, we checked mice twice daily for clinical signs of neurologic disease, which primarily included ataxia, circling, limb paralysis and weakness, twitching, and seizures. Mice displaying signs of neurologic disease were perfused transcardially with 100 U/mL heparin saline before removal of tissues. We humanely euthanized mice that did not display any signs of neurologic disease by 30 days postinoculation (dpi).

RNA Isolation and Quantitative Reverse Transcription PCR

For RNA analysis, we flash-froze spleens and brain tissue from infected mice in liquid nitrogen, then stored them at −80°C. We performed mRNA analysis as previously described (42). We amplified viral RNA from mouse tissues using the following virus-specific primers: LACV forward (5′-ATTCTACCCGCTGACCATTG-3′) and reverse (5′-GTGAGAGTGCCATAGCGTTG-3′), SSHV forward (5′-AGCATGATCAAAACGGAGGC-3′) and reverse (5′-CATGCCAATCAGACACCAGC-3′), TAHV forward (5′-AGGTCCTACATTGCCGTTCA-3′) and reverse (5′-TGGTCTACAGGTGCTAGCTC-3′), JCV forward (5′-′TATGGTTCCCCGGTAGTGTG-3′) and reverse (5′-TAACATGGTGCTTCTCGTGC-3′), and INKV forward (5′-AGTCCAAGATAAAGCCCCAGA-3′) and reverse (5′-TCATGTTAGCCTGGCATCCA-3′). We subjected primer sequences to BLAST analysis (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and tested each primer set on RNA from brains of mice infected with the 5 CSG viruses that had neurologic disease to verify virus-specific amplification by each primer set.

Immunohistochemistry

For immunohistochemistry studies, we transcardially perfused mice, removed tissues, and placed them in 10% neutral buffered formalin. After fixation, we cryoprotected tissues in 30% sucrose in PBS, embedded them in Tissue-Tek O.C.T. Compound (Sakura, https://www.sakura.eu) and froze them on dry ice; then, 10-μm sections were cut on a cryostat and mounted on slides. We washed sections with PBS and blocked for 30 minutes in blocking buffer (PBS with 5% normal donkey serum, 0.1% triton-X, and 0.3 M glycine). We diluted the primary antibody against viral antigens (in-house polyclonal antibody raised in rabbits in response to LACV infection, 1:100) and microtubule-associated protein 2 (mouse monoclonal antibody MAB3418, 1:200; Millipore, http://www.emdmillipore.com) in blocking buffer, applied these solutions to tissues, and incubated them overnight at 4°C. We washed tissue sections with PBS and incubated for 1 hour at room temperature with donkey anti-rabbit Alexa Fluor 647 (1:1,000, Life Technologies, https://www.thermofisher.com) and donkey anti-mouse Alexa Fluor 594 (1:500, Life Technologies). After washing sections again with PBS, we stained with Hoechst (1:1,000) and mounted on slides with ProLong Gold (Invitrogen, https://www.thermofisher.com). We imaged entire brain sections using the Zeiss Axio Scan.Z1 (https://www.zeiss.com) with the 40× objective lens. We acquired high-resolution images on the Zeiss 710 laser scanning microscope with the 63× objective and processed images in Imaris version 8.4.1 (https://imaris.oxinst.com) or Fiji (http://fiji.sc).

Cytotoxicity Assays

We coated 96-well plates with fibronectin as previously described and seeded 5 × 104 SH-SY5Y cells or 2 × 104 hNSCs per well. The next day, cells were inoculated with each virus in triplicate at multiplicities of infection (MOIs) of 0.1 and 0.01 for SH-SY5Y cells and 0.01 and 0.001 for hNSCs. We added Cytotox Green (Essen Bioscience, https://www.essenbioscience.com) for a final well volume of 100 μL and a final concentration of 250 nM. Cells were then imaged with an IncuCyte (Essen Bioscience) by taking 3 images per well with the 20× objective every 3 hours during a 97-hour time course. We measured confluence and fluorescent intensity using IncuCyte S3 software. We performed all statistical analyses using Prism 7.0c (https://www.graphpad.com).

Replication Kinetics

We plated and inoculated cells as described in the previous section, except that plates seeded with SH-SY5Y cells were not treated with fibronectin. We collected supernatants at 1, 6, 12, 24, 48, 72, and 96 hours postinoculation. We determined virus titers of supernatants by plaque assay using Vero cells as described previously (43). We counted LACV, TAHV, and JCV plaques at 5 dpi and SSHV and INKV plaques at 3 dpi. We performed all statistical analyses using Prism 7.0c (https://www.graphpad.com).

Results

Assessment of Neuroinvasive Disease in Mice after Intraperitoneal Inoculation with CSG Viruses

Figure 2

Thumbnail of Neuroinvasiveness of California serogroup (CSG) viruses in weanling C57BL/6 mice after intraperitoneal inoculation in study of neuropathogenesis. We inoculated 5–15 mice per group with 105 PFU of each virus (A) and 6–13 mice per group with 103 PFU of LACV, SSHV, or TAHV (B). Brains and spleens of mice were collected at the experimental endpoint and evaluated for viral RNA by quantitative reverse transcription PCR with virus-specific primers. The average of 3 mock controls is reporte

Figure 2. Neuroinvasiveness of California serogroup (CSG) viruses in weanling C57BL/6 mice after intraperitoneal inoculation in study of neuropathogenesis. We inoculated 5–15 mice per group with 105 PFU of each virus (A) and...

To determine if these 5 CSG viruses differed in their ability to enter the CNS and cause neurologic disease (i.e., neuroinvasive disease), C57BL/6 mice were inoculated intraperitoneally with a high dose (105 PFU) of each virus. Because previous studies of LACV infection showed clear age-dependent differences in disease susceptibility between weanling and adult mice, we inoculated weanling, adult, and aged mice with each virus and followed them for the development of clinical signs of neurologic disease. None of the viruses induced neuroinvasive disease in adult or aged mice after intraperitoneal inoculation (data not shown). However, neuroinvasive disease developed by 5–6 dpi in all weanling mice inoculated with 105 PFU of LACV (Figure 2, panel A), consistent with previous reports (39,44). SSHV induced neuroinvasive disease in ≈70% of weanling mice and TAHV in ≈80% of weanling mice. Neurologic signs were primarily observed at 6–7 dpi for SSHV and 5–6 dpi for TAHV. Neurologic signs were similar for LACV, SSHV, and TAHV and included ataxia, circling, limb paralysis and weakness, twitching, and seizures. JCV and INKV did not induce neuroinvasive disease in any weanling mice.

In previous studies with LACV, nearly 100% of weanling mice were susceptible to neuroinvasive disease after intraperitoneal inoculation at a dose of 103 PFU (39). To determine if TAHV and SSHV also maintain their pathogenicity at this low dose, we inoculated weanling mice intraperitoneally with 103 PFU of LACV, SSHV, or TAHV. JCV and INKV were not included in this experiment because they did not induce neuroinvasive disease at the high dose. Consistent with previous studies, 103 PFU of LACV caused disease in 100% of mice but with a slight delay in the onset of neurologic signs compared with the 105 PFU dose (Figure 2, panel B). At the low dose, SSHV induced disease in a similar percentage of mice as the high dose, whereas TAHV caused disease in only 1 of 9 mice at the low dose (Figure 2, panel B).

All weanling mice with neurologic disease had detectable viral RNA in the brain, whereas weanling, adult, and aged mice without neurologic disease had no detectable virus in the brain compared with mock controls (Figure 2, panels C, D; data not shown). Regardless of disease outcome, mice had little to no detectable viral RNA in the spleen (Figure 2, panels E, F; data not shown), suggesting clearance of virus from the periphery.

Overall, these results indicate that LACV, SSHV, and TAHV can induce neuroinvasive disease in weanling mice after intraperitoneal inoculation, whereas JCV and INKV cannot. None of the CSG viruses caused neurologic signs in adult or aged mice after intraperitoneal inoculation, suggesting an age-related susceptibility of mice to LACV-, SSHV-, and TAHV-induced neuroinvasive disease.

Assessment of Neurovirulence of CSG Viruses after Intranasal Inoculation of Mice

Figure 3

Thumbnail of Neurovirulence of California serogroup (CSG) viruses in adult, aged, and weanling mice after intranasal inoculation in study of neuropathogenesis of encephalitic CSG viruses. Groups of adult (A, B) and aged (C, D) mice (6–8 mice per group) were inoculated with 104 PFU of each virus; groups of adult (E, F) and aged (G, H) mice (6–8 mice per group) were inoculated with 102 PFU of LACV, SSHV, TAHV, and JCV; and 5 weanling mice were inoculated with 104 PFU of INKV (I, J). E, G) Survival

Figure 3. Neurovirulence of California serogroup (CSG) viruses in adult, aged, and weanling mice after intranasal inoculation in study of neuropathogenesis of encephalitic CSG viruses. Groups of adult (A, B) and aged (C,...

The inability of a virus to cause neuroinvasive disease after intraperitoneal inoculation could be due to a lack of virus replication in the periphery or an inability of the virus to gain access to the CNS. These barriers can be bypassed by intracranial or intranasal inoculation. For example, LACV is not neuroinvasive in adult mice after intraperitoneal inoculation but does cause disease in adult mice when inoculated intracranially or intranasally (39,44,45). Because none of these CSG viruses caused disease in older mice after intraperitoneal inoculation, adult and aged mice were inoculated intranasally with each virus to determine if they were neurovirulent (i.e., could replicate in the brain) and neuropathogenic (i.e., could cause disease in the brain) after a more direct inoculation route and to determine if neuropathogenesis was restricted by age. Because of the low stock concentration of some viruses, we could not inoculate mice with 105 PFU intranasally; therefore, we used a high dose of 104 PFU and a low dose of 102 PFU. At a dose of 104 PFU per mouse, all viruses except INKV induced neurologic disease in nearly all adult and aged mice (Figure 3, panels A, C). INKV was less neuropathogenic than the other CSG viruses, inducing disease in only 1 of 6 adult mice and 2 of 7 aged mice. Compared with the high dose, the low dose induced neurologic disease in a reduced percentage of mice for all viruses, except LACV in aged mice (Figure 3, panels E, G). Viral RNA was readily detectable in the brains (Figure 3, panels B, D, F, H) but not spleens (data not shown) of all mice with neurologic disease.

Because INKV induced limited disease in adult mice, we inoculated weanling mice intranasally with INKV to determine if neuropathogenicity was age dependent. Neurologic disease developed in 3 (60%) of 5 mice and was associated with viral RNA in the brain (Figure 3, panels I, J). Thus, with a high dose and direct intranasal route to the CNS, INKV was more neuropathogenic in young mice than in adults (Figure 3, panels A, I).

Figure 4

Thumbnail of Viral antigen in brains of adult and aged mice exhibiting neurologic disease after intranasal inoculation of 104 PFU of California serogroup (CSG) viruses in study of neuropathogenesis of encephalitic CSG viruses. We evaluated >4 brains from mice infected with each CSG virus, except INKV (where only 3 brains from mice with neurologic disease were available), for viral immunoreactivity. A, B) Representative images showing distribution of virus (white) and virus merged with Hoechst

Figure 4. Viral antigen in brains of adult and aged mice exhibiting neurologic disease after intranasal inoculation of 104 PFU of California serogroup (CSG) viruses in study of neuropathogenesis. We evaluated >4...

Next, we examined the distribution of the CSG viruses in the brain using immunohistochemistry. In mice inoculated intranasally with 104 PFU of LACV, SSHV, TAHV, or JCV that had neurologic disease, virus was widespread throughout the brains regardless of the day after inoculation or severity of neurologic disease (Figure 4, panels A, B). In contrast, the brains of adults and aged mice displaying neurologic disease after intranasal inoculation of INKV showed only small, sporadic patches of virus (Figure 4, panels A, B). All viruses co-localized with the neuronal marker microtubule-associated protein 2, indicating that all CSG viruses primarily infected neurons within the CNS (Figure 4, panel C). Overall, these results demonstrate that LACV, SSHV, TAHV, and JCV are neurovirulent in mice when inoculated intranasally, whereas INKV appears to be less neurovirulent and infects fewer neurons within the CNS.

Ability of CSG Viruses to Replicate in and Kill Neurons in vitro

Figure 5

Thumbnail of Cytotoxicity and viral replication kinetics assays of California serogroup (CSG) viruses in SH-SY5Y cells and human neural stem cells (hNSCs) for up to 96 hours postinoculation in study of neuropathogenesis. SH-SY5Y cells were infected at a multiplicity of infection of 0.1 (A, E, I) or 0.01 (B, F, J), and hNSCs were infected at a multiplicity of infection of 0.01 (C, G, K) or 0.001 (D, H, L). A–D) Confluence was measured over time on the IncuCyte (Essen Bioscience, https://www.essen

Figure 5. Cytotoxicity and viral replication kinetics assays of California serogroup (CSG) viruses in SH-SY5Y cells and human neural stem cells (hNSCs) for up to 96 hours postinoculation in study of neuropathogenesis. SH-SY5Y...

The differences in pathogenicity among the CSG viruses observed in mice and humans could be related to differences in their ability to infect and kill neurons. Therefore, we analyzed the ability of these viruses to replicate in and kill neurons using the human neuroblastoma cell line SH-SY5Y and hNSCs. We inoculated cells with each virus at MOIs predetermined to provide a sufficient time frame to measure virus replication before the onset of substantial cell death with LACV (MOIs of 0.1 and 0.01 for SH-SY5Y cells and MOIs of 0.01 and 0.001 for hNSCs). In SH-SY5Y cells, LACV, SSHV, and TAHV induced substantial cell death at both MOIs, whereas JCV and INKV induced little cell death (Figure 5, panels A, B, E, F). However, JCV and INKV replicated to similar titers as LACV (Table 1), albeit with a delay in replication (Table 1; Figure 5, panels I, J). In hNSCs, all 5 viruses induced cell death at both MOIs (Figure 5, panels C, D, G, H); however, LACV had a more pronounced cell death rate than the other viruses, indicating that LACV may be more neurotoxic to hNSCs than the other 4 CSG viruses, most notably INKV (Table 2; Figure 5, panels G, H). All viruses rapidly replicated to high titers at both MOIs in hNSCs; however, JCV appeared to replicate slower and reached a lower peak titer than the other CSG viruses (Table 2; Figure 5, panels K, L). All CSG viruses had significantly slower rates of growth in hNSCs with 1 or both MOIs compared with LACV (Table 2).

Together, these results suggest that LACV, SSHV, and TAHV are capable of replicating quickly to high titers in neurons and inducing substantial cell death. In contrast, INKV and JCV replicated more slowly but to similar titers. INKV and JCV also induced less cell death than the other CSG viruses, although the level of cell death varied by cell type. The lower cell death associated with INKV infection in vitro correlates with the low level of INKV infection within the CNS in vivo.

Discussion

In our study, the CSG viruses differed in pathogenesis both in mice and in vitro. Overall, LACV showed the highest neuropathogenicity and neurovirulence in vitro and in vivo, whereas INKV was the least pathogenic. These results appear to be consistent with disease patterns observed in humans, with LACV reported to cause the most neuroinvasive cases, and INKV only infrequent cases (3,4,14). Only LACV, TAHV, and SSHV were capable of causing neuroinvasive disease, a finding only observed in weanling mice. The lack of disease in adult animals is consistent with previous findings with LACV, where an age-dependent immune response in adult mice protects them from virus-induced neurologic disease (39,46).

LACV and SSHV maintained similar levels of neuroinvasiveness down to a dose of 103 PFU, whereas TAHV’s ability to induce neuroinvasive disease was greatly diminished at this low dose (Figure 2, panels A, B). The difference in dose-dependent disease susceptibility suggests that TAHV might be less virulent than LACV or SSHV. The lower virulence of TAHV than LACV or SSHV correlates with the low number of TAHV-induced neuroinvasive cases in humans, despite TAHV’s larger geographic distribution and higher rates of seroprevalence than LACV (1,2,4).

When the peripheral immune system was bypassed and adult and aged mice were inoculated intranasally, all viruses except INKV replicated extensively throughout the brain and caused neurologic disease (Figure 4). However, INKV did cause disease in a few adult and aged mice and 60% of weanling mice after intranasal inoculation, indicating INKV can be neuropathogenic under certain conditions, particularly in younger animals. These results are consistent with human case reports showing that INKV causes more severe disease in children than adults (3).

Less viral antigen was found in the brains of the 3 adult and aged INKV-inoculated mice that developed neurologic disease than in the brains from mice infected with the other CSG viruses (Figure 4). INKV induced less cell death than LACV in SH-SY5Y cells, suggesting that the lack of neuropathogenicity observed with INKV in vivo could be due to low levels of INKV-induced neuronal cell death. In addition, INKV also replicated slower than LACV in SH-SY5Y cells, suggesting the limited spread of INKV in the brains of mice might be due to inefficient replication of INKV in neurons. Further studies are needed to determine why INKV has a reduced ability to induce neuronal death compared with other CSG viruses.

In humans, JCV appears to be distinct from the other CSG viruses in that JCV preferentially causes neuroinvasive disease in adults rather than in children. Although we did not observe a similar age-dependent difference in neuroinvasion of JCV in mice, this virus did differ from the other CSG viruses. JCV (like INKV) was unable to invade the CNS, yet JCV (like LACV, SSHV, and TAHV) was highly neurovirulent in brains of mice when inoculated intranasally. However, the same high level of neurovirulence was not observed in vitro. In both SH-SY5Y cells and hNSCs, JCV induced less cell death and replicated slower than LACV. These findings suggest there might be underlying genetic differences or complexities in JCV pathogenesis not shared by any of the other CSGs.

Given that genetic variation exists within and between these encephalitic CSG viruses (30), additional differences in pathogenicity might exist for different isolates not tested in our studies. However, overall these results show that, despite being closely related, these CSG viruses differ substantially in their abilities to induce neurologic disease in mice and replicate in neurons in vitro and in vivo. Further characterization of the host and viral factors that contribute to the differences in CSG virus pathogenesis will help determine why INKV is less neurovirulent than the other CSG viruses and elucidate potential targets for CSG virus encephalitis therapies.

Dr. Evans is a postdoctoral fellow in the Laboratory of Persistent Viral Diseases at Rocky Mountain Laboratories in Hamilton, Montana, USA. Her primary research interests are in comparative viral genetics and viral-host interactions.

Top

Acknowledgments

We thank Stephen Whitehead for providing the CSG viruses, Paul Policastro for assistance with SH-SY5Y cells and hNSC cultures, and Tyson Woods for LACV stock preparation and technical assistance. We thank Austin Athman and Ryan Kissinger for the preparation of Figure 1. We thank Leonard Evans, Stefano Boi, Emmie de Wit, and Carrie Long for critical review of the manuscript. We thank the staff of the Rocky Mountain Veterinary Branch, in particular Malea Higgins and Maarit Culbert, for excellent care of the animals used in this study.

This work was supported by the National Institutes of Allergy and Infectious Diseases Division of Intramural Research, National Institutes of Health.

Top

References

  1. Drebot  MA. Emerging mosquito-borne bunyaviruses in Canada. Can Commun Dis Rep. 2015;41:117–23. DOIPubMedGoogle Scholar
  2. Hubálek  Z. Mosquito-borne viruses in Europe. Parasitol Res. 2008;103(Suppl 1):S29–43. DOIPubMedGoogle Scholar
  3. Putkuri  N, Kantele  A, Levanov  L, Kivistö  I, Brummer-Korvenkontio  M, Vaheri  A, et al. Acute human Inkoo and Chatanga virus infections, Finland. Emerg Infect Dis. 2016;22:810–7. DOIPubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. La Crosse encephalitis. Epidemiology and geographic distribution. 2018 Jan 25 [cited 2018 May 22]. https://www.cdc.gov/lac/tech/epi.html
  5. Gaensbauer  JT, Lindsey  NP, Messacar  K, Staples  JE, Fischer  M. Neuroinvasive arboviral disease in the United States: 2003 to 2012. Pediatrics. 2014;134:e642–50. DOIPubMedGoogle Scholar
  6. Lau  L, Wudel  B, Kadkhoda  K, Keynan  Y. Snowshoe hare virus causing meningoencephalitis in a young adult from northern Manitoba, Canada. Open Forum Infect Dis. 2017;4:ofx150. DOIPubMedGoogle Scholar
  7. Kilian  P, Růzek  D, Danielová  V, Hypsa  V, Grubhoffer  L. Nucleotide variability of Tahyna virus (Bunyaviridae, Orthobunyavirus) small (S) and medium (M) genomic segments in field strains differing in biological properties. Virus Res. 2010;149:119–23. DOIPubMedGoogle Scholar
  8. Pastula  DM, Hoang Johnson  DK, White  JL, Dupuis  AP II, Fischer  M, Staples  JE. Jamestown Canyon virus disease in the United States—2000–2013. Am J Trop Med Hyg. 2015;93:384–9. DOIPubMedGoogle Scholar
  9. Pastula  DM, Smith  DE, Beckham  JD, Tyler  KL. Four emerging arboviral diseases in North America: Jamestown Canyon, Powassan, chikungunya, and Zika virus diseases. J Neurovirol. 2016;22:257–60. DOIPubMedGoogle Scholar
  10. Kosoy  O, Rabe  I, Geissler  A, Adjemian  J, Panella  A, Laven  J, et al. Serological survey for antibodies to mosquito-borne bunyaviruses among US National Park Service and US Forest Service employees. Vector Borne Zoonotic Dis. 2016;16:191–8. DOIPubMedGoogle Scholar
  11. Monath  TP, Nuckolls  JG, Berall , Bauer  H, Chappell  WA, Coleman  PH. Studies on California encephalitis in Minnesota. Am J Epidemiol. 1970;92:40–50. DOIPubMedGoogle Scholar
  12. Putkuri  N, Vaheri  A, Vapalahti  O. Prevalence and protein specificity of human antibodies to Inkoo virus infection. Clin Vaccine Immunol. 2007;14:1555–62. DOIPubMedGoogle Scholar
  13. Walters  LL, Tirrell  SJ, Shope  RE. Seroepidemiology of California and Bunyamwera serogroup (Bunyaviridae) virus infections in native populations of Alaska. Am J Trop Med Hyg. 1999;60:806–21. DOIPubMedGoogle Scholar
  14. Haddow  AD, Odoi  A. The incidence risk, clustering, and clinical presentation of La Crosse virus infections in the eastern United States, 2003-2007. PLoS One. 2009;4:e6145. DOIPubMedGoogle Scholar
  15. Clark  GG, Crabbs  CL, Watts  DM, Bailey  CL. An ecological study of Jamestown Canyon virus on the Delmarva Peninsula, with emphasis on its possible vector. J Med Entomol. 1986;23:588–99. DOIPubMedGoogle Scholar
  16. Boromisa  RD, Grimstad  PR. Virus-vector-host relationships of Aedes stimulans and Jamestown Canyon virus in a northern Indiana enzootic focus. Am J Trop Med Hyg. 1986;35:1285–95. DOIPubMedGoogle Scholar
  17. Pinger  RR, Rowley  WA, Wong  YW, Dorsey  DC. Trivittatus virus infections in wild mammals and sentinel rabbits in central Iowa. Am J Trop Med Hyg. 1975;24:1006–9. DOIPubMedGoogle Scholar
  18. Heard  PB, Zhang  MB, Grimstad  PR. Isolation of Jamestown Canyon virus (California serogroup) from Aedes mosquitoes in an enzootic focus in Michigan. J Am Mosq Control Assoc. 1990;6:461–8.PubMedGoogle Scholar
  19. Anderson  JF, Main  AJ, Armstrong  PM, Andreadis  TG, Ferrandino  FJ. Arboviruses in North Dakota, 2003-2006. Am J Trop Med Hyg. 2015;92:377–93. DOIPubMedGoogle Scholar
  20. McFarlane  BL, Embil  JA, Artsob  H, Spence  L, Rozee  KR. Antibodies to the California group of arboviruses in the moose (Alces alces americana Clinton) population of Nova Scotia. Can J Microbiol. 1981;27:1219–23. DOIPubMedGoogle Scholar
  21. Berry  RL, Weigert  BJL, Calisher  CH, Parsons  MA, Bear  GT. Evidence for transovarial transmission of Jamestown Canyon virus in Ohio. Mosq News. 1977;37:494–6.
  22. Issel  CJ, Hoff  GL, Trainer  DO. Serologic evidence of infection of white-tailed deer in Texas with three California group arboviruses, (Jamestown Canyon, San Angelo, and Keystone). J Wildl Dis. 1973;9:245–8. DOIPubMedGoogle Scholar
  23. Tyers  D, Zimmer  J, Lewandowski  K, Hennager  S, Young  J, Pappert  R, et al. Serologic survey of snowshoe hares (Lepus americanus) in the Greater Yellowstone Area for brucellosis, tularemia, and snowshoe hare virus. J Wildl Dis. 2015;51:769–73. DOIPubMedGoogle Scholar
  24. Campbell  GL, Eldridge  BF, Hardy  JL, Reeves  WC, Jessup  DA, Presser  SB. Prevalence of neutralizing antibodies against California and Bunyamwera serogroup viruses in deer from mountainous areas of California. Am J Trop Med Hyg. 1989;40:428–37. DOIPubMedGoogle Scholar
  25. Eldridge  BF, Calisher  CH, Fryer  JL, Bright  L, Hobbs  DJ. Serological evidence of California serogroup virus activity in Oregon. J Wildl Dis. 1987;23:199–204. DOIPubMedGoogle Scholar
  26. Issel  CJ, Trainer  DO, Thompson  WH. Serologic evidence of infections of white-tailed deer in Wisconsin with three California group arboviruses (La Crosse, trivittatus, and Jamestown Canyon). Am J Trop Med Hyg. 1972;21:985–8. DOIPubMedGoogle Scholar
  27. Srihongse  S, Grayson  MA, Deibel  R. California serogroup viruses in New York State: the role of subtypes in human infections. Am J Trop Med Hyg. 1984;33:1218–27. DOIPubMedGoogle Scholar
  28. Walker  ED, Grayson  MA, Edman  JD. Isolation of Jamestown Canyon and snowshoe hare viruses (California serogroup) from Aedes mosquitoes in western Massachusetts. J Am Mosq Control Assoc. 1993;9:131–4.PubMedGoogle Scholar
  29. Jentes  ES, Robinson  J, Johnson  BW, Conde  I, Sakouvougui  Y, Iverson  J, et al. Acute arboviral infections in Guinea, West Africa, 2006. Am J Trop Med Hyg. 2010;83:388–94. DOIPubMedGoogle Scholar
  30. Hughes  HR, Lanciotti  RS, Blair  CD, Lambert  AJ. Full genomic characterization of California serogroup viruses, genus Orthobunyavirus, family Peribunyaviridae including phylogenetic relationships. Virology. 2017;512:201–10. DOIPubMedGoogle Scholar
  31. Pantuwatana  S, Thompson  WH, Watts  DM, Hanson  RP. Experimental infection of chipmunks and squirrels with La Crosse and Trivittatus viruses and biological transmission of La Crosse virus by Aedes triseriatus. Am J Trop Med Hyg. 1972;21:476–81. DOIPubMedGoogle Scholar
  32. Artsob  H. Distribution of California serogroup viruses and virus infections in Canada. Prog Clin Biol Res. 1983;123:277–90.PubMedGoogle Scholar
  33. Andreadis  TG, Anderson  JF, Armstrong  PM, Main  AJ. Isolations of Jamestown Canyon virus (Bunyaviridae: Orthobunyavirus) from field-collected mosquitoes (Diptera: Culicidae) in Connecticut, USA: a ten-year analysis, 1997-2006. Vector Borne Zoonotic Dis. 2008;8:175–88. DOIPubMedGoogle Scholar
  34. Kunz  C, Buckley  SM, Casals  J. Antibodies in man against Tahyna and Lumbo viruses determined by hemagglutination-inhibition and tissue-culture neutralization tests. Am J Trop Med Hyg. 1964;13:738–41. DOIPubMedGoogle Scholar
  35. Sonnleitner  ST, Lundström  J, Baumgartner  R, Simeoni  J, Schennach  H, Zelger  R, et al. Investigations on California serogroup orthobunyaviruses in the Tyrols: first description of Tahyna virus in the Alps. Vector Borne Zoonotic Dis. 2014;14:272–7. DOIPubMedGoogle Scholar
  36. Kuniholm  MH, Wolfe  ND, Huang  CYH, Mpoudi-Ngole  E, Tamoufe  U, LeBreton  M, et al. Seroprevalence and distribution of Flaviviridae, Togaviridae, and Bunyaviridae arboviral infections in rural Cameroonian adults. Am J Trop Med Hyg. 2006;74:1078–83. DOIPubMedGoogle Scholar
  37. Elliott  RM. Orthobunyaviruses: recent genetic and structural insights. Nat Rev Microbiol. 2014;12:673–85. DOIPubMedGoogle Scholar
  38. Blakqori  G, Delhaye  S, Habjan  M, Blair  CD, Sánchez-Vargas  I, Olson  KE, et al. La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts. J Virol. 2007;81:4991–9. DOIPubMedGoogle Scholar
  39. Taylor  KG, Woods  TA, Winkler  CW, Carmody  AB, Peterson  KE. Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease. J Virol. 2014;88:11070–9. DOIPubMedGoogle Scholar
  40. Bennett  RS, Gresko  AK, Murphy  BR, Whitehead  SS. Tahyna virus genetics, infectivity, and immunogenicity in mice and monkeys. Virol J. 2011;8:135. DOIPubMedGoogle Scholar
  41. Bennett  RS, Nelson  JT, Gresko  AK, Murphy  BR, Whitehead  SS. The full genome sequence of three strains of Jamestown Canyon virus and their pathogenesis in mice or monkeys. Virol J. 2011;8:136. DOIPubMedGoogle Scholar
  42. Butchi  NB, Woods  T, Du  M, Morgan  TW, Peterson  KE. TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. Am J Pathol. 2011;179:783–94. DOIPubMedGoogle Scholar
  43. Winkler  CW, Myers  LM, Woods  TA, Messer  RJ, Carmody  AB, McNally  KL, et al. Adaptive immune responses to Zika virus are important for controlling virus infection and preventing infection in brain and testes. J Immunol. 2017;198:3526–35. DOIPubMedGoogle Scholar
  44. Bennett  RS, Cress  CM, Ward  JM, Firestone  CY, Murphy  BR, Whitehead  SS. La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys. Virol J. 2008;5:25. DOIPubMedGoogle Scholar
  45. Winkler  CW, Race  B, Phillips  K, Peterson  KE. Capillaries in the olfactory bulb but not the cortex are highly susceptible to virus-induced vascular leak and promote viral neuroinvasion. Acta Neuropathol. 2015;130:233–45. DOIPubMedGoogle Scholar
  46. Winkler  CW, Myers  LM, Woods  TA, Carmody  AB, Taylor  KG, Peterson  KE. Lymphocytes have a role in protection, but not in pathogenesis, during La Crosse Virus infection in mice. J Neuroinflammation. 2017;14:62. DOIPubMedGoogle Scholar

Top

Figures
Tables

Top

Cite This Article

DOI: 10.3201/eid2504.181016

Original Publication Date: March 04, 2019

Table of Contents – Volume 25, Number 4—April 2019

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Karin E. Peterson, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Laboratory of Persistent Viral Diseases, Rocky Mountain Laboratories, 903 S 4th St, Hamilton, MT 59840, USA

Send To

10000 character(s) remaining.

Top

Page created: March 18, 2019
Page updated: March 18, 2019
Page reviewed: March 18, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external